Literature DB >> 4592596

Planning the size and duration of a clinical trial studying the time to some critical event.

S L George, M M Desu.   

Abstract

Mesh：

Year:  1974        PMID： 4592596     DOI： 10.1016/0021-9681(74)90004-6

Source DB:  PubMed          Journal:  J Chronic Dis        ISSN： 0021-9681


× No keyword cloud information.
  33 in total

1.  Duration of accrual and follow-up for two-stage clinical trials.

Authors:  L D Case; T M Morgan
Journal:  Lifetime Data Anal       Date:  2001-03       Impact factor: 1.588

2.  Sample size calculation for rank tests comparing K survival distributions.

Authors:  Sin-Ho Jung; Siu Hui
Journal:  Lifetime Data Anal       Date:  2002-12       Impact factor: 1.588

3.  Why do so many prognostic factors fail to pan out?

Authors:  S G Hilsenbeck; G M Clark; W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 4.  Optimising the economic efficiency of drug studies.

Authors:  M E Kitler
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

5.  Optimal two-stage log-rank test for randomized phase II clinical trials.

Authors:  Minjung Kwak; Sin-Ho Jung
Journal:  J Biopharm Stat       Date:  2016-04-06       Impact factor: 1.051

6.  Single-arm Phase II cancer survival trial designs.

Authors:  Jianrong Wu
Journal:  J Biopharm Stat       Date:  2015-06-22       Impact factor: 1.051

7.  Right-Sizing Adjuvant and Neoadjuvant Clinical Trials in Breast Cancer.

Authors:  Donald A Berry
Journal:  Clin Cancer Res       Date:  2015-10-28       Impact factor: 12.531

8.  Sample size and power for a logrank test and Cox proportional hazards model with multiple groups and strata, or a quantitative covariate with multiple strata.

Authors:  John M Lachin
Journal:  Stat Med       Date:  2013-05-13       Impact factor: 2.373

9.  A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group.

Authors: 
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-11       Impact factor: 10.154

10.  Adjuvant specific immunotherapy of resectable squamous cell lung carcinoma. Analysis at the eighth year.

Authors:  H Takita; A Hollinshead; T Hart; J Bhayana; R Adler; U Rao; R Moskowitz; M Ramundo
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.